Table 2.

Ongoing and planned medical intervention studies for AAA stabilization

Study acronym	Intervention	Read-out
Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA^3CT)¹⁵⁸ NCT01756833	Doxycycline 100 mg bid or placebo	2-year AAA progression (CT scan), repair or rupture
TEDY¹²⁵ NCT01683084	Telmisartan (AT₁ receptor antagonist) 40 mg or placebo.	1-year AAA progression (US and CT scan), repair or rupture
VIVAAA NCT02846883	Mesenchymal stem cells	AAA inflammation (PET-CT)
Eplerenone in the Management of abdominal aortic aneurysms. NCT02345590	Eplerenone (selective aldosterone receptor antagonist) or placebo	Not specified
TicAAA NCT02070653	Placebo or none specified dose Ticagrelor (P2Y12 inhibitor)	1-year AAA progression, surgery or repair.
FAME¹⁹² ACTRN12612001226897	Fenofibrate (PPARα agonist) 145mg or placebo 2–4 weeks prior to elective open repair	Aortic wall macrophage and osteopontin content
The Effect of Angiotensin II Type 1 Receptor Antagonists on the Size and Expansion Rate of Abdominal Aortas in Hypertensive Patients. NCT01670903	Comparison of patients treated with different classes of anti-hypertensives (AT1 receptor antagonists, ACE inhibitors, or non ARB/ACE)	Not specified
Metformin Therapy in Non-diabetic AAA Patients NCT03507413	Metformin (1000 mg BID) or placebo	1-year AAA progression (CT)
LIMIting AAA with MeTformin (LIMIT trial) Not yet registered.	Metformin or placebo	2-year AAA progression (CTA)
Inositol in the MAnaGemENt of abdominal aortic aneurysm (IMAGEN)¹⁹³	Inositol or placebo	1-year AAA progression (sack volume (CT))
Aortic Aneurysm Repression with Mesenchymal Stem Cells (ARREST) trial.¹⁹⁴	1 or 3 10⁶ cells/kg allogenic mesenchymal cells or placebo	Phase I safety trial. Circulating cytokine levels and 18-FDG/PET